ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2177 • ACR Convergence 2022

    Familial Clustering of Systemic Sclerosis, Autoimmunity, and Cancer History

    Mariana Bombini1, Nailú Sinicato1, Jacqueline Paredes2, Theresa Wampler Muskardin2, Tiago Nardi Amaral1, Ana Paula Del Rio1, Joao Marques Neto3, Timothy Niewold2 and Simone Appenzeller4, 1State University of Campinas, Campinas, São Paulo, Brazil, 2Hospital for Special Surgery, New York, NY, 3State University of Campinas, São Paulo, Brazil, 4Unicamp, Campinas, São Paulo, Brazil

    Background/Purpose: Systemic sclerosis (SSc) is a complex disease characterized by chronic inflammation, fibrosis, and vasculopathy. Genetic factors contribute to pathogenesis, but because it is a…
  • Abstract Number: 2169 • ACR Convergence 2022

    Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis

    Drashti Antala1, Angkawipa Trongtorsak1, Qingqing Meng1, Akshaya Ramachandran1, Aanshi Patel2, Pabitra Adhikari1, Prasun Pudasainee1 and Krutarth Pandya3, 1Ascension Saint Francis hospital, Evanston, IL, 2B.J. Medical College, Ahmedabad, Ahmedabad, India, 3Trumbull Regional Medical Centre, Warren, OH

    Background/Purpose: Systemic sclerosis( SSc) can primarily cause repeated focal ischaemic insults in the myocardium and result in irreversible myocardial fibrosis. Myocardial involvement, when becomes clinically…
  • Abstract Number: 2109 • ACR Convergence 2022

    Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Arthur Kavanaugh1, Gordon Lam2, Lai-shan Tam3, Natalie Shiff4, Youngja Lee5, Ana-Maria Bravo Perdomo6, May Shawi7, Elizabeth Hsia8, Emmanouil Rampakakis9 and Carlos Enrique Toro Gutiérrez10, 1University of California San Diego, La Jolla, CA, 2Arthritis and Osteoporosis Consultants of the Carolinas; Clinical Affiliate, Atrium Health and the Wake Forest School of Medicine, Cornelius, NC, 3The Chinese University of Hong Kong, Hong Kong, China, 4Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, 5Immunology Medical Affairs, Janssen Asia Pacific, Yongsan-gu, Seoul, Republic of Korea, 6Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Research and Development, LLC; University of Pennsylvania School of Medicine, Kennett Square, PA, 9McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 10Internal Medicine and Rheumatology, Reference Center for Osteoporosis, Rheumatology & Dermatology. Pontificia Javeriana University, Calí, Colombia

    Background/Purpose: Sustained minimal disease activity (MDA) is only achieved by a small portion of PsA patients (pts). Levels of disease activity consistent with MDA may…
  • Abstract Number: 2171 • ACR Convergence 2022

    Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous Systemic Sclerosis

    Ranjitha Karanth1, Giuseppina Abignano2, Vishal Kakkar1, Rebecca Ross1, Chris Denton3 and Francesco Del Galdo4, 1University of Leeds, Leeds, United Kingdom, 2Istituto Reumatologico Lucano (IReL), Azienda Ospedaliera Regionale San Carlo, Potenza, Italy, 3University College London, London, United Kingdom, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Type-I Interferon pathway activation has been associated with severity and progression of diffuse cutaneous SSc (dcSSc). The role of type-I Interferons (IFNs) in limited…
  • Abstract Number: 2160 • ACR Convergence 2022

    The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients

    Henriette Didriksen1, Øyvind Molberg2, Adi Mehta3, Suzana Jordan4, Håvard Fretheim3, Einar Gude3, Thor Ueland3, Cathrine Brunborg3, Vyacheslav Palchevskiy5, Torhild Garen3, Øyvind Midtvedt3, Arne Andreassen3, Fridtjof Lund-Johansen3, Oliver Distler4, John Belperio5 and Anna-Maria Hoffmann-Vold3, 1Oslo University Hospital, Moss, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
  • Abstract Number: 2117 • ACR Convergence 2022

    Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies

    Philip J Mease1, Laura Coates2, Robert Landewé3, Iain B McInnes4, Christopher Ritchlin5, Tatsuya Atsumi6, Frank Behrens7, Dafna Gladman8, Laure Gossec9, Peter Nash10, Barbara Ink11, Deepak Assudani11, Rajan Bajracharya11, Jason Coarse12, Adam R Prickett13 and Alice Gottlieb14, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Amsterdam University Medical Center, Meerssen, Netherlands, 4Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 5Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 6Hokkaido University, Sapporo, Japan, 7Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 8Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 9Sorbonne Université, Paris, France, 10School of Medicine, Griffith University, Sunshine Coast, Australia, 11UCB Pharma, Slough, United Kingdom, 12UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 13UCB Pharma, Brussels, Belgium, 14Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) is a disease with multiple manifestations; it is important that the efficacy of new interventions is assessed by composite endpoints across…
  • Abstract Number: 2185 • ACR Convergence 2022

    Development of a Novel Regulatory T Cell-Based Therapy for Patients with Rheumatoid Arthritis

    Anne-Renee van der Vuurst de Vries1, Kathryn Hooper1, Jonathan Graf2, Katie Tuckwell1 and Joshua Beilke1, 1Sonoma Biotherapeutics, South San Francisco, CA, 2Ucsf, San Francisco, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory condition with persistent unmet medical need despite significant treatment advances. The pathogenesis of RA is initiated…
  • Abstract Number: 2190 • ACR Convergence 2022

    Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis

    Yen Chen1, Alain Lescoat2, Dinesh Khanna3 and Susan Murphy4, 1University of Michigan, Ann Arbor, MI, 2CHU Rennes - University Rennes 1, Rennes, France, 3Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 4University of Michigan, Grosse Ile, MI

    Background/Purpose: Individuals with systemic sclerosis (SSc) report cognitive problems that worsen symptoms and daily activity performance. Compensatory cognitive strategies (CCS) are commonly taught to help…
  • Abstract Number: 2179 • ACR Convergence 2022

    Spatial and Single-Cell Transcriptomics Identify Alcam+ Macrophage / CD6+ T-Cell Interactions and Accumulation of IgG2b+ Class-Switched Plasma Cells in Marco+ Medullary Sinuses of Joint-Draining Popliteal Lymph Nodes in TNF-Tg Mice with Advanced Arthritis

    H. Mark Kenney1, Yue Peng2, Kiana Chen2, Javier Rangel-Moreno2, Elizabeth Pritchett2, Jeffrey Fox2, Benjamin Korman3, Jennifer Anolik2, Lianping Xing4, Christopher Ritchlin5, Edward Schwarz2 and Chia-Lung Wu2, 1University of Rochester Medical Center, Henrietta, NY, 2University of Rochester Medical Center, Rochester, NY, 3University of Rochester, Rochester, NY, 4University of Rochester Medical Center, Webster, NY, 5Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY

    Background/Purpose: Severe inflammatory-erosive arthritis in tumor necrosis factor transgenic (TNF-Tg) mice is associated with B-cell translocation into sinuses of joint-draining popliteal lymph nodes (PLNs) via…
  • Abstract Number: 2189 • ACR Convergence 2022

    Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study

    Janet Poole1, Deirdre Connolly2, Jessica Salazar3 and Kristine Carandang4, 1University of New Mexico, Albuquerque, NM, 2School of Medicine, Trinity College, Dublin, Ireland, 3University of New Mexico, Occupational Therapy Graduate Program, Albuquerque, NM, 4Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA

    Background/Purpose: Fatigue is one of the most prevalent and disabling symptom reported by people with systemic sclerosis (SSc). No fatigue-specific programs exist for people with…
  • Abstract Number: 2113 • ACR Convergence 2022

    Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies

    Dennis McGonagle1, Derek Haaland2, Philip Helliwell3, A. Marilise Marrache4, May Shawi5, Emmanouil Rampakakis6, Peter Nash7, Fedra Irazoque Palazuelos8 and Arthur Kavanaugh9, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 2The Waterside Clinic, Oro Medonte, ON, Canada, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Janssen Inc., Dollard-des-Ormeaux, QC, Canada, 5Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 6McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, 7School of Medicine, Griffith University, Sunshine Coast, Australia, 8Angeles Mocel Hospital; Universidad Autónoma de México, Ciudad de México, Mexico, 9University of California San Diego, La Jolla, CA

    Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria.…
  • Abstract Number: 2170 • ACR Convergence 2022

    Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis

    Francesco Del Galdo1, Suiyuan Huang2, Lesley-Anne Bissell3, sindhu johnson4, Daniel Furst5 and Dinesh Khanna6, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, 2University of Michigan, Ann Arbor, MI, 3University of Leeds, Leeds, United Kingdom, 4Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 5University of California Los Angeles, Los Angeles, CA, 6Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: The Ranked Composite Important Difference (RCID) in diffuse cutaneous Systemic Sclerosis ( dcSSc) is a clinically and patient meaningful composite score for outcome of…
  • Abstract Number: 2178 • ACR Convergence 2022

    BNT162b2 mRNA Vaccine Against Covid 19, Humoral Response, Safety and Efficacy in Scleroderma Patients

    Yolanda Braun-Moscovici1, Marielle Kaplan1, Maya Braun2, Doron Markovits3, Sami Giryes3, Kohava Toledano3, Yonit Tavor3, Katya Dolnikov3, Rula Daood3 and Alexandra Balbir-Gurman4, 1Rambam Health Care Campus and Rappaport Faculty of Medicine, Haifa, Israel, 2Hebrew University of Jerusalem, Bioinformatics, Jerusalem, Israel, 3Rambam Health Care Campus, Haifa, Israel, 4Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel

    Background/Purpose: In the begining of pandemic and till spring 2021 there were no clinical and laboratory data regarding sefety and efficacy of mRNA vaccines against…
  • Abstract Number: 2116 • ACR Convergence 2022

    Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis

    Juan Josè de Agustin1, Gustavo Añez1, delia reina2, Sergi Heredia3, Felipe Julio Ramirez Garcia4, Andrea Cuervo5, Jesus Rodriguez6, Carmen Moragues6, Patricia Moya7, Mireia Moreno8, Marta Arévalo8, Manel Pujol9, Georgina Salvador9, Noemi Busquets10, andres Ponce10, Ana Maria Laiz Alonso7 and MAria Pascual Pastor11, 1Vall D'hebron University Hospital, Barcelona, Spain, 2Complex Hospitalari Moisès Broggi, Sant Joan Despí, Catalonia, Spain, 3Complex Hospitalari Moisès Broggi, Sant Joan Despi, Catalonia, Spain, 4Hospital Clínic, Barcelona, Spain, 5Hospital Clínico y Provincial de Barcelona, Barcelona, Spain, 6Hospital Bellvitge, Hospitalet de Llobregat, Spain, 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 8Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, 9Hospital Universitario MútuaTerrassa, Terrassa, Spain, 10Hospital General de Granollers, Granollers, Spain, 11Hospital Universitari Vall d'Hebron, Barcelona, Spain

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease involving joint and enthesis disease. Ultrasound (US) has demonstrated its useful tool for the diagnosis of…
  • Abstract Number: 1996 • ACR Convergence 2022

    Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis

    Lotte van Ouwerkerk1, Patrick Verschueren2, Pascal de Jong3, Paul Emery4, Josef Smolen5, Robert Landewé6, Willem Lems7, Maarten Boers8, Tom Huizinga1, CF Allaart1 and Sytske Anne Bergstra9, 1Leiden University Medical Center, Leiden, Netherlands, 2University Hospital Leuven, Leuven, Belgium, 3ErasmusMC, Hendrik Ido Ambacht, Netherlands, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Medical University of Vienna, Vienna, Austria, 6Amsterdam University Medical Center, Meerssen, Netherlands, 7Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 9LUMC, Leiden, Netherlands

    Background/Purpose: Short-term (< 3 months) treatment with glucocorticoids (GC) ("bridging") is recommended in the EULAR 2019 rheumatoid arthritis (RA) recommendations when starting a csDMARD in…
  • « Previous Page
  • 1
  • …
  • 414
  • 415
  • 416
  • 417
  • 418
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology